First Light Asset Management LLC Acquires 16,573 Shares of AnaptysBio, Inc. $ANAB

First Light Asset Management LLC lifted its holdings in AnaptysBio, Inc. (NASDAQ:ANAB) by 2.9% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 582,004 shares of the biotechnology company’s stock after purchasing an additional 16,573 shares during the quarter. AnaptysBio comprises 2.4% of First Light Asset Management LLC’s holdings, making the stock its 17th biggest position. First Light Asset Management LLC’s holdings in AnaptysBio were worth $39,285,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. BlackRock Inc. bought a new position in AnaptysBio in the second quarter valued at approximately $124,473,000. Vanguard Group Inc. increased its position in shares of AnaptysBio by 4.5% during the fourth quarter. Vanguard Group Inc. now owns 1,544,037 shares of the biotechnology company’s stock worth $74,855,000 after acquiring an additional 67,048 shares in the last quarter. California State Teachers Retirement System increased its position in shares of AnaptysBio by 8,399.7% during the second quarter. California State Teachers Retirement System now owns 1,189,958 shares of the biotechnology company’s stock worth $80,322,000 after acquiring an additional 1,175,958 shares in the last quarter. State Street Corp raised its holdings in shares of AnaptysBio by 20.6% during the fourth quarter. State Street Corp now owns 1,053,474 shares of the biotechnology company’s stock worth $51,072,000 after acquiring an additional 180,042 shares during the period. Finally, Affinity Asset Advisors LLC raised its holdings in shares of AnaptysBio by 111.4% during the first quarter. Affinity Asset Advisors LLC now owns 940,000 shares of the biotechnology company’s stock worth $52,132,000 after acquiring an additional 495,308 shares during the period.

AnaptysBio Stock Down 1.6%

NASDAQ ANAB opened at $55.70 on Thursday. AnaptysBio, Inc. has a 12-month low of $11.40 and a 12-month high of $72.36. The company has a market capitalization of $1.65 billion, a PE ratio of -51.57 and a beta of 0.71. The firm’s 50 day moving average is $57.59 and its 200-day moving average is $59.27.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Leerink Partners set a $90.00 target price on shares of AnaptysBio in a research note on Friday, May 15th. Scotiabank downgraded AnaptysBio to a “hold” rating and set a $70.00 price target on the stock. in a research note on Tuesday, August 25th. HC Wainwright restated a “buy” rating and issued a $95.00 price target on shares of AnaptysBio in a report on Monday, August 24th. TD Cowen cut their price target on AnaptysBio from $75.00 to $70.00 and set a “buy” rating on the stock in a report on Tuesday, August 25th. Finally, UBS Group upped their price objective on AnaptysBio from $60.00 to $76.00 and gave the stock a “buy” rating in a research report on Wednesday, May 13th. Eleven equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, AnaptysBio presently has a consensus rating of “Moderate Buy” and a consensus price target of $79.85.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.